Guangzhou Wondfo Biotech Co., Ltd.

Guangzhou Wondfo Biotech Co., Ltd. is a leading in vitro diagnostics (IVD) manufacturer headquartered in Guangzhou, China, founded in 1992. The company employs over 3,000 staff and operates 20+ subsidiaries across 150+ countries. Wondfo specializes in point-of-care testing (POCT) and clinical laboratory diagnostics across eight major technology platforms: Colloidal Gold (rapid diagnostic tests for infectious disease, fertility, drugs-of-abuse); Immunofluorescence (50+ assay reagents and 7 high-performance analyzers for cardiovascular, inflammatory, renal, endocrine, and oncology biomarkers); Chemiluminescence (single-dose immunoassay analyzers with maintenance-free design); Coagulation (optical and semi-automatic blood coagulation analyzers for PT, APTT, TT, FIB, ACT); Blood Gas (portable BGA-102 analyzer delivering results in 30 seconds); Molecular Diagnostics (RT-PCR reagents and platforms for infectious disease including COVID-19); Pathology (PA-3600 automated immunohistochemical staining system); and HPLC Hemoglobin (Truth-H80E analyzer for HbA1c measurement within 60-90 seconds for diabetes diagnosis and monitoring). Products are distributed through clinical laboratories, hospitals, point-of-care settings, emergency departments, and ICUs globally. The Finecare Meter series holds the largest installed base in Chinese medical institutions. Wondfo holds WHO prequalification for select infectious disease products and maintains CE and regulatory compliance across major markets. The company supports healthcare systems with integrated POCT lab solutions and participates actively in international clinical laboratory and diagnostics conferences.